Design, biological evaluation, and molecular modelling insights of cupressic acid derivatives as promising anti-inflammatory agents. 2023

Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

The major labdanes in the oleogum resin of Araucaria heterophylla (Salisb.) Franco, 13-epi-cupressic acid (1) and acetyl-13-epi-cupressic acid (2) were used to prepare seven new (3-9), along with one known (10) derivatives. RAW264.7 cells were used to evaluate the anti-inflammatory activity of the derivatives (1-10) via measuring the level of COX-2 expression and IL-6. Pre-treated RAW264.7 cells with 1-10 (except for derivative 7) at 25 µM for 24h exhibited downregulation of COX-2 expression in response to LPS stimulation. Moreover, pre-treatment with compounds 1, 2, or 3 significantly attenuated the LPS-stimulated IL-6 level in RAW264.7 cells (p < 0.05). A docking study was conducted against phospholipase A2 (PLA2), a crucial enzyme in initiating the inflammatory cascade. The significant structural features of compounds (1-10) as PLA2 inhibitors included the carbonyl group at C-4 (free or substituted) and the hydrophobic diterpenoid skeleton. This study suggested 13-epi-cupressic acid as a scaffold for new anti-inflammatory agents.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D051546 Cyclooxygenase 2 An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS. COX-2 Prostaglandin Synthase,Cyclo-Oxygenase II,Cyclooxygenase-2,PGHS-2,PTGS2,Prostaglandin H Synthase-2,COX 2 Prostaglandin Synthase,Cyclo Oxygenase II,Prostaglandin H Synthase 2,Prostaglandin Synthase, COX-2,Synthase, COX-2 Prostaglandin
D054467 Phospholipases A2 Phospholipases that hydrolyze the acyl group attached to the 2-position of PHOSPHOGLYCERIDES. Lecithinase A2,Phospholipase A2

Related Publications

Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
January 2021, Drug design, development and therapy,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
January 2021, Current topics in medicinal chemistry,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
February 2017, Bioorganic & medicinal chemistry letters,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
February 2018, Bioorganic & medicinal chemistry letters,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
March 2015, European journal of medicinal chemistry,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
June 2023, RSC advances,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
September 2009, Bioorganic & medicinal chemistry letters,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
July 2019, Steroids,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
March 2022, Bioorganic chemistry,
Amal F Soliman, and Diaaeldin M Elimam, and Fardous F El-Senduny, and Manal A Alossaimi, and Mubarak Alamri, and Fatma M Abdel Bar
January 2017, Iranian journal of pharmaceutical research : IJPR,
Copied contents to your clipboard!